Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05755204 · ClinicalTrials.gov registry record
A Pharmacist-run PrEP Program for Women
A clinical trial, sponsored by Orlando Immunology Center.
- Terminated
- Registry status
- 2
- Enrollment target
NCT05755204 is a clinical trial that was terminated before completion, run by Orlando Immunology Center. The registered enrollment target is 2 participants.
The verdict
NCT05755204 was terminated before completion, sponsored by Orlando Immunology Center.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate uptake and retention of long acting cabotegravir (LA-CAB) also known as Apretude versus daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) also known as Truvada for PrEP among high-risk women in metro-Orlando through week 48 (to also include reasons for lack of retention in PrEP care)
Interventions
- DRUG TDF/FTC
- DRUG LA-CAB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-06-21 |
| Est. Completion | 2024-10-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05755204
The ClinicalTrials.gov registry entry for NCT05755204 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Orlando Immunology Center, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TDF/FTC is the first listed.
NCT05755204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05755204 about?
NCT05755204 is a clinical study titled "A Pharmacist-run PrEP Program for Women". The primary objective of this study is to evaluate uptake and retention of long acting cabotegravir (LA-CAB) also known as Apretude versus daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) also known as Truvada for PrEP among high-risk women in metro-Orlando through week 48 (to also i...
What is the current status of trial NCT05755204?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2023-06-21. Estimated completion is 2024-10-15.
What interventions are being tested in trial NCT05755204?
The interventions under investigation include: TDF/FTC (DRUG), LA-CAB (DRUG).
Who is sponsoring clinical trial NCT05755204?
This trial is sponsored by Orlando Immunology Center, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.